Alpa Laboratories Ltd vs Shilpa Medicare Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Alpa Laboratories Ltd is ₹ 69 as of 18 May 15:30 . The P/E Ratio of Alpa Laboratories Ltd changed from 10.5 on March 2021 to 11.2 on March 2025 . This represents a CAGR of 1.30% over 5 yearsThe P/E Ratio of Shilpa Medicare Ltd changed from 18.4 on March 2021 to 82.8 on March 2025 . This represents a CAGR of 35.10% over 5 years The Market Cap of Alpa Laboratories Ltd changed from ₹ 76.06 crore on March 2021 to ₹ 219.07 crore on March 2025 . This represents a CAGR of 23.56% over 5 yearsThe Market Cap of Shilpa Medicare Ltd changed from ₹ 2721 crore on March 2021 to ₹ 6483 crore on March 2025 . This represents a CAGR of 18.96% over 5 years The revenue of Alpa Laboratories Ltd for the Dec '25 is ₹ 29.96 crore as compare to the Sep '25 revenue of ₹ 29.32 crore. This represent the growth of 2.18% The revenue of Shilpa Medicare Ltd for the Dec '25 is ₹ 410.54 crore as compare to the Sep '25 revenue of ₹ 371.72 crore. This represent the growth of 10.44% The ebitda of Alpa Laboratories Ltd for the Dec '25 is ₹ 2.42 crore as compare to the Sep '25 ebitda of ₹ 0.82 crore. This represent the growth of 195.12% The ebitda of Shilpa Medicare Ltd for the Dec '25 is ₹ 101.9 crore as compare to the Sep '25 ebitda of ₹ 109.92 crore. This represent the decline of -7.3% The net profit of Alpa Laboratories Ltd changed from ₹ 5.1 crore to ₹ 1.9 crore over 7 quarters. This represents a CAGR of -43.12% The net profit of Shilpa Medicare Ltd changed from ₹ 14.06 crore to ₹ 44.58 crore over 7 quarters. This represents a CAGR of 93.36% The Dividend Payout of Alpa Laboratories Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Shilpa Medicare Ltd changed from 4.86 % on March 2021 to 14.01 % on March 2025 . This represents a CAGR of 23.58% over 5 years .

About Alpa Laboratories Ltd

M/s Alpa Laboratories, formed in 1967, was incorporated as Private Limited Company as 'Alpa Laboratories Private Limited' on March 18, 1988 for manufacture of pharmaceutical formulations.
In 1998, the Company was converted into a Public Limited with effect from September 3, 1998.
The facility has manufacturing areas for different Finished Dosage Forms (FDFs) including liquid injections, dry injections, tablets, capsules, eye drops, ear drops, ointments, creams and gels. In 1997, the Company initiated setting of a new manufacturing unit at Rau(Indore District), Madhya Pradesh.
The Unit commenced commercial production in the year 1999 of all types of formulations viz.
Injectables (Vials/Ampoules both liquid and Dry), tablets, capsules, eye/ear drops, ointment and creams. The company has manufacture a range of products such as ethical drugs, generic drugs, over the counter drugs (OTC) and veterinary products in various dosage forms and market them under the trade mark 'Alpa' which is a registered trademark in the name of Alpa Labs (India) Limited, a promoter group company.

About Shilpa Medicare Ltd

Shilpa Medicare Limited, formerly known as Shilpa Antibiotics Private Limited was incorporated as a Private Company on November 20, 1987.
The Company changed the status to Public and the name of the Company changed to Shilpa Antibiotics Limited in November, 1993 and later on, was changed to 'Shilpa Medicare Limited' on February 17, 2003. The Company has been promoted by Vishnukant C. Bhutada and his Associates and is engaged in manufacturing of API, Formulation and Development service.
The Company started its operations as API manufacturer way back in 1987 at Raichur, Karnataka.
It then started commercial production in November, 1989. The Company is one of the leading API and formulations manufacturers with strong capabilities in the therapeutic area of oncology.
It supplies more than 30 oncology APIs including key products such as Capecitabine, Gemcitabine Hydrochloride, Axitinib, Erlotinib Hydrochloride and Irinotecan Hydrochloride for various regulated markets including USA, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets.

FAQs for the comparison of Alpa Laboratories Ltd and Shilpa Medicare Ltd

Which company has a larger market capitalization, Alpa Laboratories Ltd or Shilpa Medicare Ltd?

Market cap of Alpa Laboratories Ltd is 147 Cr while Market cap of Shilpa Medicare Ltd is 9,358 Cr

What are the key factors driving the stock performance of Alpa Laboratories Ltd and Shilpa Medicare Ltd?

The stock performance of Alpa Laboratories Ltd and Shilpa Medicare Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Alpa Laboratories Ltd and Shilpa Medicare Ltd?

As of May 18, 2026, the Alpa Laboratories Ltd stock price is INR ₹70.14. On the other hand, Shilpa Medicare Ltd stock price is INR ₹478.5.

How do dividend payouts of Alpa Laboratories Ltd and Shilpa Medicare Ltd compare?

To compare the dividend payouts of Alpa Laboratories Ltd and Shilpa Medicare Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.